Will Tesla Stock Go Up In 2026?
EV giant Tesla (NASDAQ:TSLA) has, somewhat surprisingly, undershot the broader…
Buy
73
HRMY Quote, Financials, Valuation and Earnings
Last price:
$39.10
Seasonality move
:
-9.03%
Day range:
$38.40 - $39.55
52-week range:
$25.52 - $40.93
Dividend yield:
0%
P/E ratio:
12.23x
P/S ratio:
2.75x
P/B ratio:
2.68x
Volume:
586.2K
Avg. volume:
857.1K
1-year change:
17.45%
Market cap:
$2.2B
Revenue:
$714.7M
EPS (TTM):
$3.18
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HRMY
Harmony Biosciences Holdings, Inc.
|
$222.7M | $0.86 | 18.24% | 27.84% | $46.18 |
|
CAPR
Capricor Therapeutics, Inc.
|
$480K | -$0.54 | -100% | -240.06% | $50.80 |
|
CORT
Corcept Therapeutics, Inc.
|
$218.5M | $0.14 | 42.93% | 46.59% | $127.20 |
|
HALO
Halozyme Therapeutics, Inc.
|
$339.1M | $1.63 | 32.42% | 80.55% | $76.00 |
|
MRNA
Moderna, Inc.
|
$869.9M | -$2.16 | -34.46% | -5.24% | $35.37 |
|
NRIX
Nurix Therapeutics, Inc.
|
$13.4M | -$0.92 | -9.4% | -23.71% | $27.88 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HRMY
Harmony Biosciences Holdings, Inc.
|
$38.83 | $46.18 | $2.2B | 12.23x | $0.00 | 0% | 2.75x |
|
CAPR
Capricor Therapeutics, Inc.
|
$26.02 | $50.80 | $1.2B | -- | $0.00 | 0% | 106.12x |
|
CORT
Corcept Therapeutics, Inc.
|
$81.12 | $127.20 | $8.5B | 92.69x | $0.00 | 0% | 13.08x |
|
HALO
Halozyme Therapeutics, Inc.
|
$64.47 | $76.00 | $7.6B | 13.55x | $0.00 | 0% | 6.51x |
|
MRNA
Moderna, Inc.
|
$29.89 | $35.37 | $11.7B | -- | $0.00 | 0% | 5.19x |
|
NRIX
Nurix Therapeutics, Inc.
|
$18.84 | $27.88 | $1.4B | -- | $0.00 | 0% | 18.57x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HRMY
Harmony Biosciences Holdings, Inc.
|
21.38% | 0.639 | 14.3% | 3.46x |
|
CAPR
Capricor Therapeutics, Inc.
|
17.61% | 1.632 | 5.44% | 3.50x |
|
CORT
Corcept Therapeutics, Inc.
|
1% | -3.063 | 0.07% | 2.85x |
|
HALO
Halozyme Therapeutics, Inc.
|
74.99% | -0.702 | 17.53% | 1.26x |
|
MRNA
Moderna, Inc.
|
7.29% | 0.934 | 7.28% | 3.30x |
|
NRIX
Nurix Therapeutics, Inc.
|
13.18% | 2.105 | 7.87% | 5.21x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HRMY
Harmony Biosciences Holdings, Inc.
|
$173.8M | $65.5M | 19.81% | 25.9% | 27.35% | $108.7M |
|
CAPR
Capricor Therapeutics, Inc.
|
-$494.7K | -$26.3M | -72.3% | -77.32% | -69.16% | -$23.7M |
|
CORT
Corcept Therapeutics, Inc.
|
$203M | $10.2M | 15.84% | 16% | 4.92% | $54.5M |
|
HALO
Halozyme Therapeutics, Inc.
|
$281.3M | $217.9M | 30.69% | 139.43% | 61.51% | $175.6M |
|
MRNA
Moderna, Inc.
|
$757M | -$260M | -27.85% | -30.18% | -25.59% | -$880M |
|
NRIX
Nurix Therapeutics, Inc.
|
$2.9M | -$91.4M | -51.1% | -55.52% | -1157.65% | -$60.1M |
Harmony Biosciences Holdings, Inc. vs. Competitors
-
Which has Higher Returns HRMY or CAPR?
Capricor Therapeutics, Inc. has a net margin of 21.24% compared to Harmony Biosciences Holdings, Inc.'s net margin of -63.94%. Harmony Biosciences Holdings, Inc.'s return on equity of 25.9% beat Capricor Therapeutics, Inc.'s return on equity of -77.32%.
Company Gross Margin Earnings Per Share Invested Capital HRMYHarmony Biosciences Holdings, Inc.72.6% $0.87 $1.1B CAPRCapricor Therapeutics, Inc.-- -$0.54 $101.8M -
What do Analysts Say About HRMY or CAPR?
Harmony Biosciences Holdings, Inc. has a consensus price target of $46.18, signalling upside risk potential of 18.93%. On the other hand Capricor Therapeutics, Inc. has an analysts' consensus of $50.80 which suggests that it could grow by 95.23%. Given that Capricor Therapeutics, Inc. has higher upside potential than Harmony Biosciences Holdings, Inc., analysts believe Capricor Therapeutics, Inc. is more attractive than Harmony Biosciences Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HRMYHarmony Biosciences Holdings, Inc.7 1 0 CAPRCapricor Therapeutics, Inc.8 0 0 -
Is HRMY or CAPR More Risky?
Harmony Biosciences Holdings, Inc. has a beta of 0.801, which suggesting that the stock is 19.902% less volatile than S&P 500. In comparison Capricor Therapeutics, Inc. has a beta of 0.614, suggesting its less volatile than the S&P 500 by 38.632%.
-
Which is a Better Dividend Stock HRMY or CAPR?
Harmony Biosciences Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Capricor Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harmony Biosciences Holdings, Inc. pays -- of its earnings as a dividend. Capricor Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HRMY or CAPR?
Harmony Biosciences Holdings, Inc. quarterly revenues are $239.5M, which are larger than Capricor Therapeutics, Inc. quarterly revenues of --. Harmony Biosciences Holdings, Inc.'s net income of $50.9M is higher than Capricor Therapeutics, Inc.'s net income of -$24.6M. Notably, Harmony Biosciences Holdings, Inc.'s price-to-earnings ratio is 12.23x while Capricor Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harmony Biosciences Holdings, Inc. is 2.75x versus 106.12x for Capricor Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HRMYHarmony Biosciences Holdings, Inc.2.75x 12.23x $239.5M $50.9M CAPRCapricor Therapeutics, Inc.106.12x -- -- -$24.6M
-
Which has Higher Returns HRMY or CORT?
Corcept Therapeutics, Inc. has a net margin of 21.24% compared to Harmony Biosciences Holdings, Inc.'s net margin of 9.32%. Harmony Biosciences Holdings, Inc.'s return on equity of 25.9% beat Corcept Therapeutics, Inc.'s return on equity of 16%.
Company Gross Margin Earnings Per Share Invested Capital HRMYHarmony Biosciences Holdings, Inc.72.6% $0.87 $1.1B CORTCorcept Therapeutics, Inc.97.79% $0.16 $638.3M -
What do Analysts Say About HRMY or CORT?
Harmony Biosciences Holdings, Inc. has a consensus price target of $46.18, signalling upside risk potential of 18.93%. On the other hand Corcept Therapeutics, Inc. has an analysts' consensus of $127.20 which suggests that it could grow by 56.81%. Given that Corcept Therapeutics, Inc. has higher upside potential than Harmony Biosciences Holdings, Inc., analysts believe Corcept Therapeutics, Inc. is more attractive than Harmony Biosciences Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HRMYHarmony Biosciences Holdings, Inc.7 1 0 CORTCorcept Therapeutics, Inc.3 2 0 -
Is HRMY or CORT More Risky?
Harmony Biosciences Holdings, Inc. has a beta of 0.801, which suggesting that the stock is 19.902% less volatile than S&P 500. In comparison Corcept Therapeutics, Inc. has a beta of 0.197, suggesting its less volatile than the S&P 500 by 80.287%.
-
Which is a Better Dividend Stock HRMY or CORT?
Harmony Biosciences Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harmony Biosciences Holdings, Inc. pays -- of its earnings as a dividend. Corcept Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HRMY or CORT?
Harmony Biosciences Holdings, Inc. quarterly revenues are $239.5M, which are larger than Corcept Therapeutics, Inc. quarterly revenues of $207.6M. Harmony Biosciences Holdings, Inc.'s net income of $50.9M is higher than Corcept Therapeutics, Inc.'s net income of $19.4M. Notably, Harmony Biosciences Holdings, Inc.'s price-to-earnings ratio is 12.23x while Corcept Therapeutics, Inc.'s PE ratio is 92.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harmony Biosciences Holdings, Inc. is 2.75x versus 13.08x for Corcept Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HRMYHarmony Biosciences Holdings, Inc.2.75x 12.23x $239.5M $50.9M CORTCorcept Therapeutics, Inc.13.08x 92.69x $207.6M $19.4M
-
Which has Higher Returns HRMY or HALO?
Halozyme Therapeutics, Inc. has a net margin of 21.24% compared to Harmony Biosciences Holdings, Inc.'s net margin of 49.46%. Harmony Biosciences Holdings, Inc.'s return on equity of 25.9% beat Halozyme Therapeutics, Inc.'s return on equity of 139.43%.
Company Gross Margin Earnings Per Share Invested Capital HRMYHarmony Biosciences Holdings, Inc.72.6% $0.87 $1.1B HALOHalozyme Therapeutics, Inc.79.39% $1.43 $2B -
What do Analysts Say About HRMY or HALO?
Harmony Biosciences Holdings, Inc. has a consensus price target of $46.18, signalling upside risk potential of 18.93%. On the other hand Halozyme Therapeutics, Inc. has an analysts' consensus of $76.00 which suggests that it could grow by 17.88%. Given that Harmony Biosciences Holdings, Inc. has higher upside potential than Halozyme Therapeutics, Inc., analysts believe Harmony Biosciences Holdings, Inc. is more attractive than Halozyme Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HRMYHarmony Biosciences Holdings, Inc.7 1 0 HALOHalozyme Therapeutics, Inc.4 2 1 -
Is HRMY or HALO More Risky?
Harmony Biosciences Holdings, Inc. has a beta of 0.801, which suggesting that the stock is 19.902% less volatile than S&P 500. In comparison Halozyme Therapeutics, Inc. has a beta of 0.948, suggesting its less volatile than the S&P 500 by 5.224%.
-
Which is a Better Dividend Stock HRMY or HALO?
Harmony Biosciences Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Halozyme Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harmony Biosciences Holdings, Inc. pays -- of its earnings as a dividend. Halozyme Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HRMY or HALO?
Harmony Biosciences Holdings, Inc. quarterly revenues are $239.5M, which are smaller than Halozyme Therapeutics, Inc. quarterly revenues of $354.3M. Harmony Biosciences Holdings, Inc.'s net income of $50.9M is lower than Halozyme Therapeutics, Inc.'s net income of $175.2M. Notably, Harmony Biosciences Holdings, Inc.'s price-to-earnings ratio is 12.23x while Halozyme Therapeutics, Inc.'s PE ratio is 13.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harmony Biosciences Holdings, Inc. is 2.75x versus 6.51x for Halozyme Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HRMYHarmony Biosciences Holdings, Inc.2.75x 12.23x $239.5M $50.9M HALOHalozyme Therapeutics, Inc.6.51x 13.55x $354.3M $175.2M
-
Which has Higher Returns HRMY or MRNA?
Moderna, Inc. has a net margin of 21.24% compared to Harmony Biosciences Holdings, Inc.'s net margin of -19.69%. Harmony Biosciences Holdings, Inc.'s return on equity of 25.9% beat Moderna, Inc.'s return on equity of -30.18%.
Company Gross Margin Earnings Per Share Invested Capital HRMYHarmony Biosciences Holdings, Inc.72.6% $0.87 $1.1B MRNAModerna, Inc.74.51% -$0.51 $10.1B -
What do Analysts Say About HRMY or MRNA?
Harmony Biosciences Holdings, Inc. has a consensus price target of $46.18, signalling upside risk potential of 18.93%. On the other hand Moderna, Inc. has an analysts' consensus of $35.37 which suggests that it could grow by 18.33%. Given that Harmony Biosciences Holdings, Inc. has higher upside potential than Moderna, Inc., analysts believe Harmony Biosciences Holdings, Inc. is more attractive than Moderna, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HRMYHarmony Biosciences Holdings, Inc.7 1 0 MRNAModerna, Inc.3 16 1 -
Is HRMY or MRNA More Risky?
Harmony Biosciences Holdings, Inc. has a beta of 0.801, which suggesting that the stock is 19.902% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.109, suggesting its more volatile than the S&P 500 by 10.882%.
-
Which is a Better Dividend Stock HRMY or MRNA?
Harmony Biosciences Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harmony Biosciences Holdings, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HRMY or MRNA?
Harmony Biosciences Holdings, Inc. quarterly revenues are $239.5M, which are smaller than Moderna, Inc. quarterly revenues of $1B. Harmony Biosciences Holdings, Inc.'s net income of $50.9M is higher than Moderna, Inc.'s net income of -$200M. Notably, Harmony Biosciences Holdings, Inc.'s price-to-earnings ratio is 12.23x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harmony Biosciences Holdings, Inc. is 2.75x versus 5.19x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HRMYHarmony Biosciences Holdings, Inc.2.75x 12.23x $239.5M $50.9M MRNAModerna, Inc.5.19x -- $1B -$200M
-
Which has Higher Returns HRMY or NRIX?
Nurix Therapeutics, Inc. has a net margin of 21.24% compared to Harmony Biosciences Holdings, Inc.'s net margin of -1094.77%. Harmony Biosciences Holdings, Inc.'s return on equity of 25.9% beat Nurix Therapeutics, Inc.'s return on equity of -55.52%.
Company Gross Margin Earnings Per Share Invested Capital HRMYHarmony Biosciences Holdings, Inc.72.6% $0.87 $1.1B NRIXNurix Therapeutics, Inc.36.66% -$1.03 $428.7M -
What do Analysts Say About HRMY or NRIX?
Harmony Biosciences Holdings, Inc. has a consensus price target of $46.18, signalling upside risk potential of 18.93%. On the other hand Nurix Therapeutics, Inc. has an analysts' consensus of $27.88 which suggests that it could grow by 48%. Given that Nurix Therapeutics, Inc. has higher upside potential than Harmony Biosciences Holdings, Inc., analysts believe Nurix Therapeutics, Inc. is more attractive than Harmony Biosciences Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HRMYHarmony Biosciences Holdings, Inc.7 1 0 NRIXNurix Therapeutics, Inc.12 1 0 -
Is HRMY or NRIX More Risky?
Harmony Biosciences Holdings, Inc. has a beta of 0.801, which suggesting that the stock is 19.902% less volatile than S&P 500. In comparison Nurix Therapeutics, Inc. has a beta of 1.874, suggesting its more volatile than the S&P 500 by 87.383%.
-
Which is a Better Dividend Stock HRMY or NRIX?
Harmony Biosciences Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nurix Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harmony Biosciences Holdings, Inc. pays -- of its earnings as a dividend. Nurix Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HRMY or NRIX?
Harmony Biosciences Holdings, Inc. quarterly revenues are $239.5M, which are larger than Nurix Therapeutics, Inc. quarterly revenues of $7.9M. Harmony Biosciences Holdings, Inc.'s net income of $50.9M is higher than Nurix Therapeutics, Inc.'s net income of -$86.4M. Notably, Harmony Biosciences Holdings, Inc.'s price-to-earnings ratio is 12.23x while Nurix Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harmony Biosciences Holdings, Inc. is 2.75x versus 18.57x for Nurix Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HRMYHarmony Biosciences Holdings, Inc.2.75x 12.23x $239.5M $50.9M NRIXNurix Therapeutics, Inc.18.57x -- $7.9M -$86.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Are the Best AI Power Stocks?
As the construction of AI infrastructure accelerates, the gap between…
Is IONQ The Best Quantum Stock to Buy?
Riding a wave of investor enthusiasm for the technology, quantum…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
40
HUT alert for Dec 17
Hut 8 Corp. [HUT] is up 12.16% over the past day.
Sell
39
SMX alert for Dec 17
SMX (Security Matters) Plc [SMX] is up 21.37% over the past day.
Sell
45
ZBIO alert for Dec 17
Zenas BioPharma, Inc. [ZBIO] is down 2.95% over the past day.
